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Abstract
Background: The Australian/Canadian hand Osteoarthritis Index (AUSCAN) and the Western Ontario and McMaster
Universities knee and hip Osteoarthritis Index (WOMAC) are the most commonly used clinical tools to manage and
monitor osteoarthritis (OA). Few studies have as yet reported longitudinal changes in the AUSCAN index regarding
the hand. While there are published data regarding WOMAC assessments of the hip and the knee, the two sites
have always evaluated separately. The current study therefore sought to determine the minimal clinically important
difference (MCID) in decline in the AUSCAN hand and WOMAC hip/knee physical function scores over 1 year using
anchor-based and distribution-based methods.
Methods: The study analysed data collected by the European Project on Osteoarthritis, a prospective observational
study investigating six adult cohorts with and without OA by evaluating changes in the AUSCAN and WOMAC
physical function scores at baseline and 12–18 months later. Pain and stiffness scores, the performance-based grip
strength and walking speed and health-related quality of life measures were used as the study’s anchors. Receiver
operating characteristic curves and distribution-based methods were used to estimate the MCID in the AUSCAN
and WOMAC physical function scores; only the data of those participants who possessed paired (baseline and
follow up-measures) AUSCAN and WOMAC scores were included in the analysis.
Results: Out of the 1866 participants who were evaluated, 1842 had paired AUSCAN scores and 1845 had paired
WOMAC scores. The changes in the AUSCAN physical function score correlated significantly with those in the
AUSCAN pain score (r = 0.31). Anchor- and distribution-based approaches converged identifying 4 as the MCID for
decline in the AUSCAN hand physical function. Changes in the WOMAC hip/knee physical function score were
significantly correlated with changes in both the WOMAC pain score (r = 0.47) and the WOMAC stiffness score
(r = 0.35). The different approaches converged identifying two as the MCID for decline in the WOMAC hip/knee
physical function.
Conclusions: The most reliable MCID estimates of decline over 1 year in the AUSCAN hand and WOMAC hip/knee
physical function scores were 4 and 2 points, respectively.
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Background
The Australian/Canadian Hand Osteoarthritis Index
(AUSCAN) [1] and the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) [2, 3] scales
are self-report instruments measuring pain, stiffness and
physical function linked to osteoarthritis (OA), and have
been used by the European Project on Osteoarthritis
(EPOSA) to assess personal and societal variables af-
fected by OA, such as quality of life (QoL), social partici-
pation, and health care use in several ageing European
cohorts. The individuals enrolled in the project were re-
ceiving treatment for severe OA, had undiagnosed or
untreated OA or did not have OA at all [4].
The Minimum Clinically Important Difference
(MCID) is defined as the smallest change in a score that
a patient perceives as beneficial or detrimental [5]. There
are different types of MCID, depending on whether
there has been an improvement or a worsening in the
variable being measured and on the external standard
being employed [6].
Until now, to our knowledge, the MCID in the AUS-
CAN hand and WOMAC hip/knee physical function
scales has received scarce attention. Specifically few
studies report longitudinal changes in the AUSCAN [7].
While some studies have investigated the WOMAC
scales [7–9], the two sites of hip and knee have always
been evaluated separately [10–15]. Moreover, the MCID
has almost always been considered from an improve-
ment perspective, as the majority of studies have aimed
to examine the efficacy of pharmacological interventions
[11, 13], rehabilitation programs [8, 9], and/or of surgical
treatments [10, 12, 14, 15].
The aim of the current study was therefore to estimate
the MCID in the AUSCAN and WOMAC physical func-
tion subscales using distribution-based and anchor-based
methods for longitudinal changes. We postulated that the
AUSCAN and the WOMAC physical function scores
would worsen [16, 17] with time (i.e., there would be a rise
in both) and that the changes in the AUSCAN and
WOMAC physical function scores would correlate signifi-
cantly with changes in other well-established OA health
variables or performance-based measures [18–25].
Methods
Participants
The current study analysed data collected by the European
Project on OSteoArthritis (EPOSA), a population-based
study involving cohorts living in Germany, Italy, the
Netherlands, Spain, Sweden, and the UK, that re-
cruited 2942 adults between the ages of 65–85. All
the participants gave written informed consent; the
study design and methodology are outlined in detail
elsewhere [4]. The study design was granted approval
by the appropriate local ethics committees (Germany:
Universitat Ulm Ethikkommission [312/08]. Italy:
Comitato Etico Provinciale Treviso [XLIV-RSA/
AULSS7]. The Netherlands: Medisch Ethische Toet-
singscommissie Vrije Universiteit Amsterdam [2002/
141]. Spain: Comité Ético de Investigación Clínica del
Hospital Universitario La Paz Madrid [PI-1080].
Sweden: Till forskningsetikkommittén vid Karolinska
Instituted Stockholm [00–132]. UK: Hertfordshire Re-
search Ethics Committee [10/H0311/59]).
The project aimed to evaluate the participants once at
baseline (between November 2010 and November 2011)
and a second time 12–18months later. During the as-
sessment the participants underwent a clinical examin-
ation and were interviewed at home or in a health care
centre by trained physicians and nurses using a stan-
dardized questionnaire.
Measures
Physical function, pain and stiffness of hand OA were
assessed at baseline and 12–18 months later using the
three subscales of the AUSCAN (15 items grouped into
3 scales: pain (5 items), stiffness (1 item), and physical
function (9 items)) that utilized a 5-point Likert scale
(responses ranged from none to extreme; 0 = none, 1 =
mild, 2 =moderate, 3 = severe, and 4 = extreme) [1].
Physical function, pain and stiffness of hip and/or knee
OA were measured at baseline and 12–18months later
using the three subscales of the WOMAC (24 items
grouped into 3 scales: pain (5 items), stiffness (2 items),
and physical function (17 items)) that utilized a 5-point
Likert scale. Hip/knee pain and stiffness were defined as
the maximum value of two joints [2, 3].
All the AUSCAN and WOMAC subscales were nor-
malized from 0 to 100; higher scores indicate worse
health status [1–3].
The Grip strength of both hands at baseline and 12–
18months later was measured twice, using a strain
gauge dynamometer and the result (the highest values of
the right and left hands were summed and divided by 2)
is expressed in kilograms [26].
Walking speed was measured by time, registered in
seconds, for a 3-m course marked out on the floor with
no obstructions for an additional 2 ft at both ends.
Anxiety and depression were evaluated at baseline and
12–18months later using the Hospital Anxiety and De-
pression Scales (HADS), a 14-item self-assessment in-
strument that measures anxiety and/or depression
separately [27]. Scores that are 8 or higher (scores range
between 0 and 21) on each/either of the subscales indi-
cate altered states.
Health-related QoL was measured at baseline and 12–
18months later using: the 5-level EQ-5D, consisting of a
descriptive system comprising five dimensions (mobility,
self care, usual activities, pain/discomfort, anxiety/
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depression) and the EQ VAS, a vertical visual analogue
scale [28]. The scores of the EQ-5D were converted into a
single index, based on general population surveys, using
the time trade-off (TTO) valuations from the general popu-
lation of the UK; scores between − 0.594 and 1. 1 indicate
good or satisfying health. Scores of the EQ-VAS range be-
tween 0 and 100, with higher scores indicating better
health.
Clinical diagnosis of OA was formulated on the basis
of the participant’s medical history and a physical exam-
ination (only at baseline), utilising algorithms in accord-
ance with the clinical criteria developed by the
American College of Rheumatology (ACR) [29] and the
recommendations of the European League Against
Rheumatism [30].
Clinical hand OA (classified as present vs absent) was
diagnosed using specific AUSCAN sections [1]: the cut-off
in the algorithm for hand pain was ≥3 and it was ≥1 for
stiffness. At least 2 of the following criteria were required
for a diagnosis of hand OA: a) hard tissue enlargement of
two or more joints, b) hard tissue enlargement of two or
more distal inter-phalangeal joints, c) deformity of at least
one hand joint. Swelling of the metacarpophalangeal joints
criteria was a variable that was assessed only in the English
and German participants.
Clinical hip/knee OA, defined as the presence of OA
in at least one or both of these joints, was diagnosed on
the basis of the outcome of specific WOMAC sections.
Pain in the hip/knee on at least one side [2, 3] was eval-
uated during the physical examination using a cut-off
≥3. For the participants, to be diagnosed with knee OA,
at least two of the following were necessary: a) a morn-
ing stiffness score from mild to extreme; b) crepitus with
active motion on at least one side at the physical exam-
ination; c) bone tenderness on at least one side at the
physical examination; d) bone enlargement at the phys-
ical examination on at least one side; e) no palpable
warmth of synovium at the physical examination in ei-
ther knees. All of the following were needed for a posi-
tive hip OA assessment: a) pain in the hip on at least
one side associated with restricted hip internal rotation
at a physical examination; b) morning stiffness of the hip
lasting < 60 min, evaluated using the stiffness section of
the WOMAC with a score from mild to extreme.
Statistical analysis
Data analyses and graphical presentations were carried
out using SAS software (SAS System, SAS Institute Inc.,
Cary, NC), version 9.4. Data were analysed using a set of
weights calculated per sex and per 5-year age class with
respect to the 2010 Standard European Population [4].
The changes over times (in the 12–18months between
the baseline evaluation and the follow-up one) were evalu-
ated as continuous variables using the non-parametric
signed rank test. Spearman’s correlation was used to com-
pare the changes in the AUSCAN and WOMAC physical
function scales and the changes in the other variables; the
Cronbach α coefficient was used to measure the scales’ re-
liability (internal consistency) (values of α ≥ 0.7 reflect a
good reliability) [31].
Only the data of the participants whose assessments
were considered complete, that is they had completed
both the baseline and follow-up assessments, were in-
cluded in the statistical analysis. The MCID was cal-
culated by measuring the changes from basal to
follow-up measurements scores. Since the MCID for
subject-reported outcome measures may vary in dif-
ferent populations and depending on the context, as
recommended by Revicki et al. [32], we used multiple
approaches to estimate the MCID in the AUSCAN
and WOMAC physical function scores to triangulate
on a single value or on a small range of values.
For anchor-based estimation of MCID we used the
receiver operating characteristic (ROC) curve on the
change score in the anchor. The variables assessed as
possible anchors for the AUSCAN hand OA physical
function score were: the AUSCAN for hand OA Pain,
the AUSCAN for hand OA Stiffness, the Grip strength,
the HADS anxiety, the HADS depression, the EQ-5D-5
L, and the EQ VAS. The variables evaluated as possible
anchors for the WOMAC for hip/knee OA physical
function score were: the WOMAC for hip/knee OA
Pain, the WOMAC for hip/knee OA Stiffness, the
Walking-test time, the HADS anxiety, the HADS de-
pression, the EQ-5D-5 L, and the EQ VAS.
An anchor should be chosen because of a significant
correlation between the change in the physical function
score and the change in the anchor and a correlation co-
efficient ≥ |0.30| [31].
A ROC curve was constructed for those participants
showing stable or worsened anchor scores; the area
under the curve (AUC) summarizes the instrument’s
ability to distinguish between individuals who have or
do not have a minimal clinically important difference
in functionality. The criteria used to calculate the
probability of an optimal cut-off were: the Youden
index (J) [33], the Euclidean distance (D), and the
equality sensitivity and specificity (S). The percentage
of participants exceeding the MCID were estimated
for each cut-off value.
The following were considered for the distribution
based-methods:
1. A standardized response mean (SRM) [34],
representing very small (SRM2), moderate (SRM5)
and large changes (SRM8) [35].
2. The standard error of measurement (SEM) [36] of
the changes, considering a 63% confidence interval
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(CI) (SEM63), a 90% CI (SEM90), and a 95% CI
(SEM95).
3. The Edwards-Nunnally (EN) method [37], at the
90% CI (EN90), and at the 95% CI (EN95).
Anchor-based and distribution-based-methods were
used to determine the MCID, and on that basis the par-
ticipants were divided into two categories: worse/no
worse functionality at the second assessment point. Tri-
angulation was used to examine multiple values from
different approaches to converge on a single value, with
Cohen’s k (range from − 1 to 1, with one indicating a
perfect agreement).
Results
Out of the original 2942 participants who completed the
baseline evaluation (Fig. 1), 2455 (83%) agreed to
undergo a follow-up evaluation 12–18months later. It
was not possible to re-evaluate 487 participants (16.6%
of the baseline sample) because they had died, were un-
traceable, or declined to participate. The non-completers
were significantly older, more likely to be female, less ed-
ucated, and predominantly Italian with respect to the
completers.
Since information from the German group was incom-
plete, data from that country (n = 336, 14% of 2455),
were not analysed. The data that was analysed and upon
which our results are therefore based represents 1866
participants who completed both of the study’s evalua-
tions. One thousand, eight hundred forty-two of these
had paired AUSCAN measurements and 1845 had
paired WOMAC measurements.
Table 1 (weighted data) shows that approximately 17%
of the participants had clinical hand OA and more than
22% had clinical hip/knee OA. The median changes in
the physical function scores detected using the AUS-
CAN hand and WOMAC hip/knee subscales were sig-
nificant, as were the median changes in the WOMAC
stiffness score. There were no significant changes in the
AUSCAN pain and stiffness subscales and in the
WOMAC pain subscale over time.
All other changes in grip strength, walking-test time,
the HADS scales, and the EQ-5D-5 L were significant
over time.
Table 2 shows the correlation coefficient in the change
in the AUSCAN and the WOMAC physical function
scores and in the change in the other measures that were
considered as possible anchors. For the hand, only the
changes in the AUSCAN pain scores were significantly
Baseline              
2,942
Died, untraceable, 
declined to participate            
487 (16.6%) 
Follow-up            
2,455 (83.4%)
Germany                
336 (13.7%)
Italy, the Netherlands, 
Spain, Sweden, UK     
2,119 (87.3%)
No complete        
253 (11.9%)
Complete        
1,866 (88.1%)
AUSCAN 
complete             
1,842 (86.9%)
WOMAC 
complete            
1,845 (87.1%) 
Fig. 1 Persons recruited and analysed
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correlated with a coefficient greater than |0.3| (r = 0.31)
with the changes in the AUSCAN physical function
scores. For the hip/knee, both the changes in the
WOMAC pain scores and the changes in the WOMAC
stiffness scores were correlated with the changes in the
WOMAC physical function score with respectively a cor-
relation coefficient of 0.47 and 0.35 (greater than |0.3|).
The AUSCAN and WOMAC physical function scores
showed a very good reliability of coefficient (Cronbach’s
α of 0.92 and 0.94 respectively).
AUSCAN physical function estimates of MCID
Using hand pain as an external anchor, the estimates of
the MCID in the AUSCAN hand physical function were
consistent and equal to one. The only divergent criteria
was the Youden index according to which the estimated
MCID for the hand was four. Using distribution-based
methods, the estimate for significant worsening in the
AUSCAN physical function score ranged from 1 to 8.
Based on these cut-offs, the participants were divided
into worse vs not worse in functionality 12–18months
after baseline (Fig. 2).
When the percentage of values obtained with
distribution-based MCID methods were compared with
those produced by anchor-based methods, the two sets
agreed most strongly according to Cohen’s k. The first
set (k values at approximately 0.97) formed by the ROC
D Euclidean distance, the ROC S for equal sensitivity
and specificity, and the SRM2, identified approximately
34–35% of the participants with clinically significant
physical function decline at the 12–18 month follow-up
evaluation. The second set (k values ranging from 0.95
Table 1 Baseline characteristics and change in physical function and in the anchors after 12–18 months
Baseline Change: 12–18 months follow-up - baseline P
Age, n, mean (SD), median (IQR), y 1886 73.8 ± 5.0 73 (70.77)
Female Sex, n (%) 1886 977 (51.8)
High education, n (%) 1886 1120 (58.8)
Country, n (%) 1886
Italy 312 (16.8)
The Netherlands 407 (22.0)
Spain 413 (22.4)
Sweden 392 (23.0)
UK 362 (15.8)
Clinical hand OA, n (%) 1886 1842 (16.7)
Clinical hip/knee OA, n (%) 1886 1845 (22.6)
AUSCAN for hand OAa, n, mean ± SD, median (IQR)
Physical function 1842 9.1 ± 15.4 0 (0,11) 1842 1.1 ± 11.3 0 (0,4) <.0001
Painc 1842 7.6 ± 15.2 0 (0,5) 1842 1.7 ± 14.4 0 (0,0) 0.1949
Stiffness 1842 10.0 ± 18.7 0 (0,25) 1842 1.0 ± 17.2 0 (0,0) 0.1358
WOMAC for hip/knee OAa, n, mean ± SD, median (IQR)
Physical function 1845 8.5 ± 13.2 2 (0,12) 1845 1.5 ± 11.3 0 (−1,4) 0.0123
Pain 1845 10.0 ± 14.3 5 (0,15) 1845 1.4 ± 13.2 0 (−5,5) 0.2579
Stiffness 1845 12.9 ± 18.6 0 (0,25) 1845 0.3 ± 17.9 0 (0,12) 0.0390
Grip strengthb, n, mean ± SD, median (IQR), kg 1862 27.7 ± 10.2 26 (20,35) 1826 −1.1 ± 5.8 −1 (−3.5,1.5) 0.0004
Walking-test timec, n, mean ± SD, median (IQR), sec 1854 3.3 ± 1.6 3 (2.3,3.8) 1830 0.1 ± 1.6 0 (−0.5,0.6) <.0001
HADS anxietyd, n, mean ± SD, median (IQR) 1886 4.5 ± 3.5 4 (2,7) 1872 −0.6 ± 2.6 −1 (−2,1) <.0001
HADS depressiond, n, mean ± SD, median (IQR) 1886 3.5 ± 3.0 3 (1,5) 1875 −0.3 ± 2.4 0 (−1,1) <.0001
EQ-5D-5 Le, n, mean ± SD, median (IQR) 1876 0.8 ± 0.2 0.8 (0.7,1.0) 1855 0.0 ± 0.2 0 (0.0,0.1) 0.0059
EQ VASf, n, mean ± SD, median (IQR) 1882 76.5 ± 16.2 80 (70,90) 1875 −0.5 ± 15.6 0 (−10,5) 0.0114
Weighted data. Numbers of subjects, age, and sex were unweighted data. Except where indicated otherwise, values are the percent of subjects
EPOSA European Project on OSteoArthritis, SD Standard deviation, IQR interquartile range, AUSCAN AUStralian/CANadian Osteoarthritis Hand Index, WOMAC
Western Ontario and McMaster Universities Osteoarthritis Index, OA osteoarthritis, HADS Hospital Anxiety and Depression Scales, EQ-5D-5 L Health status using five
dimensions, EQ VAS Health status using the visual analogue scale
a Possible scores range from 0 to 100, with 100 indicating worse health status. b Lower values indicate worse performance. c Higher values indicate worse
performance. d Possible scores range from 0 to 21, a score ≥ 8 indicates anxiety and/or depression. e Possible scores range from − 0.594 to 1, lower values
indicating worse health status. f Possible scores range from 0 to 100, with 0 indicating worse health status
The P are bold where they are less than or equal to the significance level cut-off of 0.05
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to 1) which was formed by the ROC J Youden index, the
SRM5, and the SEM63, uncovered that 24% of the par-
ticipants had a clinically significant decline. In view of
the concordance and the recommendation to privilege
the anchor-based methods [32], we compared the MCID
based on the ROC J/SEM63 and the one based on the
ROC D/S. Out of the 639 worse participants identified
by the ROC D/S criterion, 453 were the same ones iden-
tified by ROC J/SEM63. The MCID based on the ROC
J/SEM63, which estimated a change of 4 points, was
found to be the most reliable criterion to analyse the loss
of hand functionality at 12–18 months.
WOMAC physical function estimates of MCID
Using hip/knee pain and stiffness scales as external an-
chors, the estimates of the MCID of the WOMAC hip/
knee physical function were consistent, although the
magnitude of the correlations can only be considered
24.6%
34.7%
34.7%
33.6%
22.8%
12.8%
24.6%
17.9%
13.3%
18.9%
14.3%
75.4%
65.3%
65.3%
66.4%
77.2%
87.2%
75.4%
82.1%
86.7%
81.1%
85.7%
0 10 20 30 40 50 60 70 80 90 100
J
D
S
SRM2
SRM5
SRM8
SEM63
SEM90
SEM95
EN90
EN95
Worse Not worse
ROC pain
Fig. 2 Estimates of MCID percentages for the AUSCAN hand physical function. AUSCAN: Australian/Canadian Hand Osteoarthritis Index; MCID:
Minimum Clinically Important Difference; ROC pain: receiver operating characteristic using the AUSCAN pain score as the anchor; J: point that
maximizes the Youden index; D: point that minimizes the Euclidean distance; S: point that minimizes the equality sensitivity, specificity. SRM:
standardized response mean; SRM2: SRM with Cohen’s threshold 0.20; SRM5: SRM with Cohen’s threshold 0.50; SRM8: SRM with Cohen’s threshold
0.80; CI: Confidence Interval; SEM: Standard Error Measurement; SEM63: SEM with 63% CI; SEM90: SEM with 90% CI; SEM95: SEM with 95% CI; EN:
Edwards-Nunnally index; EN90: EN with 90% CI; EN95: EN with 95% CI
Table 2 Correlation among change in physical function with change in the anchors
Change AUSCAN for hand OA Physical function (n = 1842) WOMAC for hip/knee OA Physical function (n = 1845)
Anchors r P r P
AUSCAN for hand OA Pain 0.30742 <.0001
AUSCAN for hand OA Stiffness 0.21075 <.0001
WOMAC for hip/knee OA Pain 0.46557 <.0001
WOMAC for hip/knee OA Stiffness 0.34937 <.0001
Grip strength −0,10,451 <.0001
Walking-test time 0.06917 0.0034
HADS anxiety 0.02249 0.3363 0.11065 <.0001
HADS depression 0.04346 0.0630 0.12391 <.0001
EQ-5D-5 L −0.11449 <.0001 −0.15293 <.0001
EQ VAS −0.07177 0.0021 −0.10105 <.0001
AUSCAN AUStralian/CANadian Osteoarthritis Hand Index, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, OA osteoarthritis, HADS Hospital
Anxiety and Depression Scales, EQ-5D-5 L health status using five dimensions, EQ VAS health status using the visual analogue scale, r Spearman’s
correlation coefficient
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moderate. The ROC analysis of the anchor responses to
the WOMAC pain and stiffness scales estimated that the
MCID was almost always one. Once again, the divergent
criteria was the Youden index with stiffness as the an-
chor that estimated a two point MCID for hip/knee
physical function.
Using distribution-based methods, the estimate for
significant worsening in the WOMAC physical func-
tion score ranges from 1 to 9. Figure 3 shows the
percentage of participants who had worse hip/knee
functionality 12–18 months after baseline according to
the different methods utilized. The MCIDs for hip/
knee physical function decline that showed the high-
est degree of agreement were: those based on the
SRM2, those that used the WOMAC pain score as
the anchor minimized the Euclidean distance and the
equality sensitivity and specificity as well as those that
maximized the Youden index (k = 0.94). The SRM2
also agreed with those that, using the WOMAC stiff-
ness score as the anchor, minimized the Euclidean
distance and the equality sensitivity and specificity
(k = 0.94), or maximized the Youden index (k = 1).
These methods identified 30 and 33% of participants
with clinically significant hip/knee physical function
decline 12–18 months after baseline respectively. Fi-
nally, there was a strong agreement (k = 0.89) be-
tween the SEM63 and the Youden index with the
stiffness score used as an anchor; they respectively
detected 26 and 30%.of the participants.
As the highest degree of agreement was found be-
tween the Youden index (using ROC with stiffness
as the anchor) and the SRM2, the MCID based on
these criteria seemed to be the most suitable one to
analyse the loss of hip/knee functionality at 12–18
months. Both criteria were consistent in identifying
two as the best discriminating WOMAC physical
function change cut-off.
Discussion
While it is true that the AUSCAN and WOMAC scales
are the most commonly used clinical tools to manage
and monitor OA patients, to our knowledge the MCID
for decline picked up by these measures has never been
evaluated. Only the study of Angst et al. [9], which fo-
cused on patients with OA of the lower extremities after
a rehabilitation intervention, reported a MCID showing
worsening in the WOMAC hip/knee physical function
of approximately 1.33, based on a scale from 0 to 10.
The study’s initial premise that hand and hip/knee phys-
ical function would deteriorate significantly over a year’s
time was confirmed by our data showing higher AUS-
CAN and WOMAC physical function scores.
Although the relevance of the MCID approach re-
mains controversial and despite the fact that physical
32.5%
32.5%
32.5%
30.0%
32.5%
32.5%
30.0%
21.7%
14.5%
25.6%
21.7%
19.2%
22.2%
20.2%
67.5%
67.5%
67.5%
70.0%
67.5%
67.5%
70.0%
78.3%
85.5%
74.4%
78.3%
80.8%
77.8%
79.8%
0 10 20 30 40 50 60 70 80 90 100
J
D
S
J
D
S
SRM2
SRM5
SRM8
SEM63
SEM90
SEM95
EN90
EN95
Worse Not worse
ROC stiffness
ROC pain
Fig. 3 Estimates of MCID percentages for the WOMAC hip/knee physical function. WOMAC, Western Ontario and McMaster Universities; MCID:
Minimum Clinically Important Difference; ROC pain: receiver operating characteristic using the WOMAC pain score as the anchor; ROC stiffness:
receiver operating characteristic using the WOMAC stiffness score as the anchor; J: point that maximizes the Youden index; D: point that
minimizes the Euclidean distance; S: point that minimizes the equality sensitivity, specificity. SRM: standardized response mean; SRM2: SRM with
Cohen’s threshold 0.20; SRM5: SRM with Cohen’s threshold 0.50; SRM8: SRM with Cohen’s threshold 0.80; CI: Confidence Interval; SEM: Standard
Error Measurement; SEM63: SEM with 63% CI; SEM90: SEM with 90% CI; SEM95: SEM with 95% CI; EN: Edwards-Nunnally index; EN90: EN with 90%
CI; EN95: EN with 95% CI
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function values can depend on the population being ex-
amined, the context, the time and methods used [25], it
remains an important assessment instrument. The mag-
nitude of the MCID was inferior in the participants
studied here using the WOMAC instrument with re-
spect to other studies [7–15]. As those studies focused
on patients before and after interventions, the differ-
ences in the magnitude of the MCID might be con-
nected to patient expectations regarding surgical
interventions, as compared to non-surgical interventions
[38]. Other factors that might explain the differing
MCID values could be: the severity of the participant’s
baseline health status, the length of the period being ex-
amined, the accuracy of the measurement instruments,
and the direction in the change in the MCID (i.e. to-
wards improvement or worsening).
Other studies have demonstrated that changes in the
AUSCAN and WOMAC physical function scores correl-
ate significantly with changes in other generic, adapted, or
performance-based measures used to gauge pain and
function in the hand and hip/knee OA [18–25]. Our study
did not, however, find any correlations between the
changes in the AUSCAN and WOMAC physical function
and the changes in other more generic measures such as
the Hospital Anxiety and Depression Scale and the Euro-
pean QoL Surveys. The anchors with the strongest corre-
lations were the pain-specific questionnaires (AUSCAN
and WOMAC pain subscale), presumably because they
are basically measures of pain during physical activities ra-
ther than unspecific pain measures [39].
The estimates of the MCID in both the AUSCAN
hand physical function and the WOMAC hip/knee phys-
ical function according to the ROC analysis using differ-
ent anchor responses and criteria, were consistent. The
only divergent criteria was the Youden index that over-
estimated the MCIDs.
But as explained above, besides an anchor-based
method, we also used a distribution-based approach to
estimate the MCID, given that the two are complemen-
tary [40]. Distribution-based approaches, which are
based on the statistical characteristics of the samples
studied and reliable measures, generated a wide range of
different estimates of the MCID for the AUSCAN hand
and WOMAC hip/knee physical function that were
greater than the anchor-based estimates. Both methods
converged to a common result.
While distribution-based estimates are able to furnish
supportive information when the change is significant,
they do not provide a direct measure of minimum clinic-
ally important difference. That is why precedence was
shown to the anchor based estimates. Moreover, since
the MCIDs estimated using distribution-based methods
were greater than the mean change reported 12–18
months after baseline, it is possible that the data from
the distribution-based methods provide information
about clinical significance but might overestimate the
true MCID.
This study has several limitations. First, the changes in
outcome measures could hypothetically be associated
with baseline levels. Second, there is the possibility that
the participants selected did not experience much or any
change over the 12–18month study period. Third, there
may be even important differences in the populations
studied and in the cut-off values of the MCID physical
function decline. Indeed, estimates can differ depending
on the instrument, domain, country, and condition, at
least for condition-specific measures, and further re-
search is required before the estimates presented here
can be generalized to other instruments [7].
The study’s most important strength was undeniably
its large population base: the participants were randomly
selected from older community-dwelling European pop-
ulations. Not only persons with OA but also large num-
bers of healthy individuals not affected with OA were
analysed. The methodology used was the same in all of
the countries, and OA was diagnosed in accordance with
standardized international guidelines [4]. Our study was
based on valid standardized globalized measures (the
WOMAC and AUSCAN Indexes) suggested by guidance
documents [41, 42], and, in fact, they proved to be quite
reliable. The data are longitudinal in nature. Another
study strength was that it describes the decision-making
process leading to the selection of a single value from a
range of different MCID cut offs by comparing the per-
centages of change scores exceeding the MCID. The
process considered the major concordance between
those based on anchor-based methods and those based
on distribution-based approaches, privileging those
based on the former [40, 43, 44], and evaluated the dif-
ferences in terms of clinical OA.
Conclusion
To conclude, the study shows that the AUSCAN hand
and WOMAC hip/knee physical function scores are in-
deed sensitive to the effects of OA. The data analysed
using various health and physical performance measures
as external anchors showed that the minimally import-
ant decline over 1 year in the AUSCAN and WOMAC
physical function scores was four and two points re-
spectively. Further research is required to confirm the
robustness of these estimates and to evaluate their tem-
poral consistency and country-dependency.
Abbreviation
AUSCAN: Australian/Canadian Hand Osteoarthritis hand Index; CI: Confidence
Interval; EN: Edwards-Nunnally index; EN90: EN with 90% CI; EN95: EN with
95% CI; EPOSA: European Project on OSteoArthritis; EQ VAS: Health status
using the visual analogue scale; EQ-5D-5 L: Health status using five
dimensions; HADS: Hospital Anxiety and Depression Scales; IQR: interquartile
range; MCID: Minimum Clinically Important Difference; ROC: Receiver
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operating characteristic; SD: Standard deviation; SEM: Standard Error
Measurement; SEM63: SEM with 63% CI; SEM90: SEM with 90% CI;
SEM95: SEM with 95% CI; SRM: standardized response mean; SRM2: SRM with
Cohen’s threshold 0.20; SRM5: SRM with Cohen’s threshold 0.50; SRM8: SRM
with Cohen’s threshold 0.80; WOMAC: Western Ontario and McMaster
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